Stocks Health care PBLS
NASDAQ · Health careParabilis Medicines, Inc. (PBLS)
At June 30, 2026 it held $1.1B in cash against $6.4M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.
Key facts about Parabilis Medicines, Inc.
- Net worth
- Parabilis Medicines, Inc. has a market value (market cap) of $3.7B at the latest share price. A company's "net worth" usually means this market value or the shareholders' equity on its balance sheet.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 13, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
What Parabilis Medicines, Inc. does
Parabilis Medicines, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker PBLS.
Earnings: every quarter and the next report date
Latest SEC filings
What Parabilis Medicines, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 5, 2026
- September 15, 2026
- September 2, 2026
- August 25, 2026
- August 14, 2026Passive stake (5% or more) SCHEDULE 13G
- August 13, 2026Quarterly report 10-Q · period to June 30, 2026Revenue was $148K; diluted EPS -$2.32 versus -$22.28.
- August 13, 2026
- August 6, 2026Passive stake (5% or more) SCHEDULE 13G
- June 18, 2026Activist stake (5% or more) SCHEDULE 13D
- June 11, 2026
Insider trades
What the people running Parabilis Medicines, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| July 22, 2026 | Ra Capital Management, L.P.Director, 10% owner | Boughtindirect | 47,250 | $1.4M |
| July 21, 2026 | Ra Capital Management, L.P.Director, 10% owner | Boughtindirect | 21,696 | $606.6K |
| July 21, 2026 | Ra Capital Management, L.P.Director, 10% owner | Boughtindirect | 6,504 | $189.7K |
| July 21, 2026 | Ra Capital Management, L.P.Director, 10% owner | Boughtindirect | 37,723 | $1.1M |
| July 20, 2026 | Ra Capital Management, L.P.Director, 10% owner | Boughtindirect | 98,433 | $2.7M |
| July 20, 2026 | Ra Capital Management, L.P.Director, 10% owner | Boughtindirect | 32,987 | $914.4K |
| June 15, 2026 | Sebulsky AlanDirector | Boughtindirect | 5,000 | $130K |
| June 15, 2026 | Sebulsky AlanDirector | Boughtindirect | 4,065 | $110.1K |
Who owns PBLS
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| RA Capital Management, L.P.13D, may seek influence with 3 related filers | 23.8% | June 18, 2026 |
| Fmr LLC13G, passive with 1 related filers | 8.5% | August 6, 2026 |
| ARCH Venture Fund XII, L.P.13G, passive with 6 related filers | 5.3% | August 14, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 79 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| RA Capital Management, L.P. | 28,933,371 | new |
| Fmr LLC | 10,292,735 | new |
| ARCH Venture Management, LLC | 6,412,780 | new |
| venBio Partners LLC | 5,266,697 | new |
| Alphabet Inc. | 4,919,498 | new |
| Nextech Invest Ltd. | 4,663,176 | new |
| Cormorant Asset Management, LP | 4,615,612 | new |
| Regeneron Pharmaceuticals, Inc. | 4,166,666 | new |
| Siren, L.L.C. | 2,992,259 | new |
| Farallon Capital Management, L.L.C. | 2,368,200 | new |
| Jupiter Topco LLC | 2,296,547 | new |
| Frazier Life Sciences Management, L.P. | 1,920,805 | new |
| Deerfield Management Company, L.P. | 1,880,704 | new |
| General Catalyst Group Management, LLC | 1,600,937 | new |
| General Atlantic, L.P. | 1,538,461 | new |
| Soleus Capital Management, L.P. | 1,465,070 | new |
| Vanguard Portfolio Management LLC | 1,302,479 | new |
| Vanguard Capital Management LLC | 1,156,962 | new |
| Jpmorgan Chase & Co | 1,042,772 | new |
| Foresite Capital Management VI LLC | 999,044 | new |
Insiders
6 insiders reported holding 28,147,210 shares in total, about $856M at the last price.
| Holder | Shares |
|---|---|
| Ra Capital Management, L.P.Director, 10% owner | 26,529,68626,529,686 held indirectly |
| Flynn James E10% owner | 940,352940,352 held indirectly |
| Levy Guy10% owner | 527,070527,070 held indirectly |
| Borisy AlexisDirector | 105,414 |
| Sebulsky AlanDirector | 30,00030,000 held indirectly |
| Fitzgerald Edward MDirector | 14,688 |
Questions about PBLS
What does Parabilis Medicines, Inc. do?
Parabilis Medicines, Inc. is a company in the Health care sector, listed on NASDAQ as PBLS. Its shares trade on NASDAQ under the ticker PBLS.
What is Parabilis Medicines, Inc.'s net worth?
Parabilis Medicines, Inc. has a market value (market cap) of $3.7B at the latest share price. A company's "net worth" usually means this market value or the shareholders' equity on its balance sheet.
When did Parabilis Medicines, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the material agreement from November 5, 2026.
Similar companies
Compare PBLS with
Follow PBLS
Get an email when Parabilis Medicines, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Parabilis Medicines, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.